Is anyone aware of the pharmacological difference between mpc...

Is anyone aware of the pharmacological difference between mpc 150 and remestemcel?
just to add to the yankee’s post The presence of cardiomyopathy secondary to sepsis is thought to be multi factorial and at a very basic level consists of some of the following:
- presence/up-regulation of inflammatory cytokines, interluekins, especially 1 and 8 and TNFalpha
- impaired ATP production and development of nitric oxide
-altered calcium homeostasis
-impaired B adrenergic signalling
-distributive shock leading to myocardial ischemia
-catecholamine excess also attributing to myocardial ischemia.

I believe a large portion of this is combatted through the use of remestemcel L and if given earlier will stop the progression to most of the causes of permanent myocardial damage. They have already demonstrated that IL 1 alone reduced cardiac damage and improved mortality in septic patients, so I can’t see how we wouldn’t, being a much more broad spectrum immunomodulatory treatment.
If you want to read more of the pathophysiogy behind cardiac dysfunction in sepsis this May help, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4474734/